I believe individualized therapy based on the best current studies can lead to creative solutions to impossible problems, like curing cancer for good.
Where I see patients (2)
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface.
Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT.
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
The Journal of clinical investigation